BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Not Applicable

• Conditions: Macula Lutea Degeneration
• Interventions: Drug: intravitreal injection

• Registration Number: NCT04882956
• Lead Sponsor: Benha University

Brief Summary

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Detailed Description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)

Study Timeline

• Study Start: 2020-08-05
• Status Verified: 2021-05
• Study First Submitted: 2021-05-06
• Study First Submitted QC: 2021-05-11
• Last Update Submitted: 2021-05-11
• Study First Posted: 2021-05-12
• Last Update Posted: 2021-05-12
• Primary Completion: 2021-12
• Study Completion: 2022-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• • Age-Related macular neovascularization degeneration

Exclusion Criteria

• other causes of macular neovascularization degeneration
• other macular diseases

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BEOVU	intravitreal injection	Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
Eylea	intravitreal injection	Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity (BCVA)	12 months	Change in BCVA in LOG MARS(logarithm minimum angle of resolution

Trial Locations

Locations (1)

INMC; 🇦🇪 Abu Dhabi, United Arab Emirates